264 related articles for article (PubMed ID: 21908573)
1. Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Cruz CR; Gerdemann U; Leen AM; Shafer JA; Ku S; Tzou B; Horton TM; Sheehan A; Copeland A; Younes A; Rooney CM; Heslop HE; Bollard CM
Clin Cancer Res; 2011 Nov; 17(22):7058-66. PubMed ID: 21908573
[TBL] [Abstract][Full Text] [Related]
2. MAGE: the spell is broken.
Rezvani K
Clin Cancer Res; 2011 Nov; 17(22):6955-7. PubMed ID: 22068655
[TBL] [Abstract][Full Text] [Related]
3. Decitabine enhances tumor recognition by T cells through upregulating the MAGE-A3 expression in esophageal carcinoma.
Shi X; Chen X; Fang B; Ping Y; Qin G; Yue D; Li F; Yang S; Zhang Y
Biomed Pharmacother; 2019 Apr; 112():108632. PubMed ID: 30797153
[TBL] [Abstract][Full Text] [Related]
4. MAGE-A1, MAGE-A3, and NY-ESO-1 can be upregulated on neuroblastoma cells to facilitate cytotoxic T lymphocyte-mediated tumor cell killing.
Bao L; Dunham K; Lucas K
Cancer Immunol Immunother; 2011 Sep; 60(9):1299-307. PubMed ID: 21626030
[TBL] [Abstract][Full Text] [Related]
5. Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK; Wang Y; Sundaram K; Bai F; Lucas KG
Tumour Biol; 2017 Jul; 39(7):1010428317701309. PubMed ID: 28677424
[TBL] [Abstract][Full Text] [Related]
6. Potential role of 5-aza-2'-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer.
Gunda V; Cogdill AP; Bernasconi MJ; Wargo JA; Parangi S
Surgery; 2013 Dec; 154(6):1456-62; discussion 1462. PubMed ID: 24238058
[TBL] [Abstract][Full Text] [Related]
7. Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.
Krishnadas DK; Bao L; Bai F; Chencheri SC; Lucas K
Tumour Biol; 2014 Jun; 35(6):5753-62. PubMed ID: 24584817
[TBL] [Abstract][Full Text] [Related]
8. DNA methyltransferase inhibition increases efficacy of adoptive cellular immunotherapy of murine breast cancer.
Terracina KP; Graham LJ; Payne KK; Manjili MH; Baek A; Damle SR; Bear HD
Cancer Immunol Immunother; 2016 Sep; 65(9):1061-73. PubMed ID: 27416831
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.
Roskrow MA; Suzuki N; Gan Yj; Sixbey JW; Ng CY; Kimbrough S; Hudson M; Brenner MK; Heslop HE; Rooney CM
Blood; 1998 Apr; 91(8):2925-34. PubMed ID: 9531603
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma.
Krishnadas DK; Shusterman S; Bai F; Diller L; Sullivan JE; Cheerva AC; George RE; Lucas KG
Cancer Immunol Immunother; 2015 Oct; 64(10):1251-60. PubMed ID: 26105625
[TBL] [Abstract][Full Text] [Related]
11. Increased PRAME antigen-specific killing of malignant cell lines by low avidity CTL clones, following treatment with 5-Aza-2'-Deoxycytidine.
Yan M; Himoudi N; Basu BP; Wallace R; Poon E; Adams S; Hasan F; Xue SA; Wilson N; Dalgleish A; Williams O; Anderson J
Cancer Immunol Immunother; 2011 Sep; 60(9):1243-55. PubMed ID: 21553146
[TBL] [Abstract][Full Text] [Related]
12. Induction of a specific CD8+ T-cell response to cancer/testis antigens by demethylating pre-treatment against osteosarcoma.
Li B; Zhu X; Sun L; Yuan L; Zhang J; Li H; Ye Z
Oncotarget; 2014 Nov; 5(21):10791-802. PubMed ID: 25301731
[TBL] [Abstract][Full Text] [Related]
13. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules.
Adair SJ; Hogan KT
Cancer Immunol Immunother; 2009 Apr; 58(4):589-601. PubMed ID: 18791715
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.
Gerdemann U; Katari U; Christin AS; Cruz CR; Tripic T; Rousseau A; Gottschalk SM; Savoldo B; Vera JF; Heslop HE; Brenner MK; Bollard CM; Rooney CM; Leen AM
Mol Ther; 2011 Dec; 19(12):2258-68. PubMed ID: 21915103
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease.
Bollard CM; Aguilar L; Straathof KC; Gahn B; Huls MH; Rousseau A; Sixbey J; Gresik MV; Carrum G; Hudson M; Dilloo D; Gee A; Brenner MK; Rooney CM; Heslop HE
J Exp Med; 2004 Dec; 200(12):1623-33. PubMed ID: 15611290
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy.
Kalra M; Gerdemann U; Luu JD; Ngo MC; Leen AM; Louis CU; Rooney CM; Gottschalk S
Cytotherapy; 2019 Feb; 21(2):212-223. PubMed ID: 30396848
[TBL] [Abstract][Full Text] [Related]
18. Low-dose decitabine induces MAGE-A expression and inhibits invasion via suppression of NF-κB2 and MMP2 in Eca109 cells.
Liu WH; Sang MX; Hou SY; Zhang C; Shan BE
Biomed Pharmacother; 2014 Jul; 68(6):745-50. PubMed ID: 25123082
[TBL] [Abstract][Full Text] [Related]
19. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells.
Wagner HJ; Bollard CM; Vigouroux S; Huls MH; Anderson R; Prentice HG; Brenner MK; Heslop HE; Rooney CM
Cancer Gene Ther; 2004 Feb; 11(2):81-91. PubMed ID: 14685154
[TBL] [Abstract][Full Text] [Related]
20. A MAGE-A4 peptide presented by HLA-A2 is recognized by cytolytic T lymphocytes.
Duffour MT; Chaux P; Lurquin C; Cornelis G; Boon T; van der Bruggen P
Eur J Immunol; 1999 Oct; 29(10):3329-37. PubMed ID: 10540345
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]